We manufacture and sell a variety of new and generic drugs, including antidepressants and anti-allergic agents, that have been widely used in the medical field for many years.

We are also proactively creating new drugs, such as the anticonvulsant MIDAFRESA^®, which offers a new treatment option for status epilepticus, and the antiepileptic drug SABRIL^®, which was approved through a joint development effort.

We are working to bring drugs—that have already been approved overseas as effective treatments—to the Japanese market for diseases that still lack a treatment option or where treatment satisfaction is low.
MODIODAL^®, the sleep disorder treatment, had been approved and sold in many countries worldwide before Alfresa Pharma obtained manufacturing and marketing approval for it as a treatment of excessive daytime sleepiness associated with narcolepsy. We have since obtained approval to prescribe the drug for sleep apnea syndrome and idiopathic hypersomnia.
In September 2025, we obtained manufacturing and marketing approval for the epinephrine nasal spray NEFFY^® as a new treatment option for anaphylaxis. We worked to quickly bring NEFFY^®, a drug developed in the United States, to the Japanese market to improve patients’ quality of life through the drug’s ease of administration and portability.